Strs Ohio Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Posted by Brenda Bartman on Jul 7th, 2026

Strs Ohio lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 899.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,775 shares of the biopharmaceutical company’s stock after purchasing an additional 24,996 shares during the quarter. Strs Ohio’s holdings in Halozyme Therapeutics were worth $1,795,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in HALO. DLD Asset Management LP increased its position in Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after buying an additional 5,000,000 shares in the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics in the fourth quarter worth $128,201,000. William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $124,031,000. Voloridge Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the third quarter worth $77,587,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Halozyme Therapeutics during the second quarter valued at $51,295,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.8%

Shares of HALO stock traded up $0.67 during mid-day trading on Tuesday, hitting $81.45. The company’s stock had a trading volume of 129,992 shares, compared to its average volume of 1,791,465. Halozyme Therapeutics, Inc. has a 52-week low of $54.15 and a 52-week high of $82.26. The business has a 50-day moving average price of $69.69 and a 200 day moving average price of $69.58. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock has a market cap of $9.66 billion, a price-to-earnings ratio of 29.17, a PEG ratio of 0.33 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period last year, the firm posted $1.11 earnings per share. Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 72,179 shares of company stock worth $5,052,400. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HALO shares. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. UBS Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Get Our Latest Stock Analysis on HALO

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.